SODIUM BICARBONATE injection, solution

Страна: САЩ

Език: английски

Източник: NLM (National Library of Medicine)

Купи го сега

Активна съставка:

SODIUM BICARBONATE (UNII: 8MDF5V39QO) (SODIUM CATION - UNII:LYR4M0NH37, BICARBONATE ION - UNII:HN1ZRA3Q20)

Предлага се от:

Hospira, Inc.

Начин на приложение:

INTRAVENOUS

Вид предписание :

PRESCRIPTION DRUG

Терапевтични показания:

Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time int

Каталог на резюме:

Sodium Bicarbonate Injection USP, 8.4% is supplied as 25 vials per carton in the following dosage form. NDC No. (Unit of Sale) 0409-6625-14 NDC No. (Each) 0409-6625-22 Dosage Form Flip Top Vial Conc. % 8.4 mg/mL (NaHCO3 ) 84 mEq/mL (Na+ ) 1 mEq/mL (HCO3 ¯) 1 mEq/Container Size (mL) 50/50 mOsm/mL 1.56 pH 7.8 (7.0–8.5) Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. Distributed by: Hospira, Inc., Lake Forest, IL 60045 USA LAB-1158-3.0 05/2018

Статус Оторизация:

Abbreviated New Drug Application

Данни за продукта

                                SODIUM BICARBONATE- SODIUM BICARBONATE INJECTION, SOLUTION
HOSPIRA, INC.
----------
SODIUM
BICARBONATE RX
ONLY
INJECTION USP, 8.4%
FOR THE CORRECTION OF METABOLIC ACIDOSIS
AND OTHER CONDITIONS REQUIRING SYSTEMIC ALKALINIZATION.
FLIP TOP VIAL
DESCRIPTION
Sodium Bicarbonate Injection, USP is a sterile, nonpyrogenic,
hypertonic solution of
sodium bicarbonate (NaHCO ) in water for injection for administration
by the
intravenous route as an electrolyte replenisher and systemic
alkalizer.
The solution is offered in a concentration of 8.4% with a pH of 7.8
(7.0 to 8.5). Carbon
dioxide or nitrogen may be used to adjust pH. See table in HOW
SUPPLIED section for
contents and characteristics.
The solution contains no bacteriostat, antimicrobial agent or added
buffer and is
intended only for use as a single-dose injection. When smaller doses
are required, the
unused portion should be discarded with the entire unit.
Sodium bicarbonate, 84 mg is equal to one milliequivalent each of Na
and HCO ¯.
Sodium Bicarbonate, USP is chemically designated NaHCO , a white
crystalline powder
soluble in water.
Water for Injection, USP is chemically designated H O.
CLINICAL PHARMACOLOGY
Intravenous sodium bicarbonate therapy increases plasma bicarbonate,
buffers excess
hydrogen ion concentration, raises blood pH and reverses the clinical
manifestations of
acidosis.
Sodium bicarbonate in water dissociates to provide sodium (Na ) and
bicarbonate
(HCO ¯ ) ions. Sodium (Na ) is the principal cation of the
extracellular fluid and plays a
large part in the therapy of fluid and electrolyte disturbances.
Bicarbonate (HCO ¯ ) is a
normal constituent of body fluids and the normal plasma level ranges
from 24 to 31
mEq/liter. Plasma concentration is regulated by the kidney through
acidification of the
urine when there is a deficit or by alkalinization of the urine when
there is an excess.
Bicarbonate anion is considered "labile" since at a proper
concentration of hydrogen ion
3
+
3
3
2
+
3
+
3
+
(H ) it may be converted to carbonic acid (H CO ) and th
                                
                                Прочетете целия документ
                                
                            

Сигнали за търсене, свързани с този продукт

Преглед на историята на документите